3 Dividend Winners For Your Portfolio: AstraZeneca plc, Direct Line Insurance Group plc & Tullett Prebon plc

Should you buy AstraZeneca plc (LON: AZN), Direct Line Insurance Group plc (LON: DLG) and Tullett Prebon (LON: TLPR)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Are you looking to top up your investment portfolio, and buy some new shares? Well, how about these three companies? In this article I will debate the pros and cons of buying into a pharmaceutical firm, an insurer and a broker. Let’s start with the drugs company…


The world is getting more populous, and also more wealthy. These certain demographic trends mean that there will be a bright future for Big Pharma.

Of the drugs companies, one of my picks is AstraZeneca (LSE: AZN). What appeals to me about this business is its unerring focus on scientific research as the means to long-term profitability.

Instead of messing about with the tax rules, like Pfizer is doing, or acquiring other companies, AZ’s route to riches is innovation. And it is working. Its portfolio of anti-cancer drugs is amongst the strongest in the medical industry. And the breadth of its past winners means that it will also do well as countries such as India, China and Malaysia expand their healthcare systems.

Astra’s recent successes have already driven the share price higher, but I think there is more to come from this company. A predicted 2015 P/E ratio of 15.93, with a juicy 4.12% dividend yield means this pharma business is fairly priced, and a decent income buy.

Direct Line Group

Another high-yield star I’d like to pick is Direct Line Group (LSE: DLG), an insurance company which has been rising steadily over the past year. This is one of the most dependable companies you can think of, generating prodigious amounts of cash year-in and year-out.

Despite recent price rises, this firm is still reasonably priced, with a forecast P/E ratio of 13.00 and a dividend yield of 3.42%. The sustained and growing profitability of this business is demonstrated by the earnings per share progression:

2012: 13.42p
2013: 22.58p
2014: 25.96p
2015: 29.05p
2016: 27.62p

This is another income share to tuck away in your portfolio.

Tullett Prebon

Tullett Prebon (LSE: TLPR) is a broker which is currently in talks to takeover the broking business of its competitor ICAP.

This is a strong and highly profitable business, which will stand to gain by consolidating the interdealer broking sector. It is also keenly priced, with a P/E ratio of 9.09 and an attractive dividend yield of 4.83%, which is well covered by its profits.

Increased regulation in banking and markets is driving this consolidation, and I think Tullett could well end up as a big fish in the pond of inter-dealing broking. So this company is another of my dividend picks.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

Why wait? I’d buy FTSE 100 shares now before the next stock market rally!

Our writer explains why he'd snap up what he sees as bargain FTSE 100 shares now rather than waiting in…

Read more »

Investing Articles

Is it time for me to change my tune about Rolls-Royce shares?

This Fool has steered clear of buying Rolls-Royce shares. But after its recent performance, he's reconsidering his stance. Here's why.

Read more »

Investing Articles

Aviva share price: 3 reasons to consider buying for 2024

The Aviva share price is still lower then when I bought some nearly a decade ago. Here's why I'm thinking…

Read more »

Front view photo of a woman using digital tablet in London
Investing Articles

These 2 shares could bank me £328 a month in second income

Jon Smith runs through two FTSE stocks that have above-average dividend yields that could pay out a generous second income…

Read more »

Stack of one pound coins falling over
Investing Articles

This passive income plan is simple – but could earn me thousands!

Christopher Ruane explains how putting a fiver a day to work in the stock market might help him earn thousands…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on

After record profits, are Lloyds shares a buy, sell, or hold?

As Lloyds pulls in pre-tax profits of £7.5bn, boosts its dividend, and continues to repurchase shares, are the company’s shares…

Read more »

Investing Articles

NatWest shares: is a once-in-a-lifetime opportunity on the way?

Should investors get ready for a unique opportunity as the UK government plans to sell off its NatWest shares later…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

3 charts that indicate this FTSE 100 stock is a once-in-a-decade passive income opportunity

The dividend yield on Unilever shares is at a 10-year high. And Stephen Wright also sees positive signs for the…

Read more »